These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388 [TBL] [Abstract][Full Text] [Related]
17. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750 [TBL] [Abstract][Full Text] [Related]
18. Personalized Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283 [TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours. Alsadik S; Yusuf S; Al-Nahhas A Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538 [TBL] [Abstract][Full Text] [Related]
20. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]